2024 Medical IP Practice Training Programme (Session 1 · Beijing)
About the Conference
About the Conference
The Medical IP Practice Training Programme is a series jointly launched by the IP Practice Centre (BIPI) and Zhichan Huicui. Session 1 was held on 29-30 March 2024 at the Yiling Building in Beijing, with instructors drawn from experts, judges and lawyers who have worked in pharmaceutical IP for many years.
This session was built around the innovator drug perspective, with nearly thirty participants from R&D, IP management and legal practice at pharmaceutical companies. The curriculum ran from the institutional framework through prosecution and drafting, invalidation and infringement litigation, forming a complete practical chain for innovator drug IP.
Five instructors covered China's biopharma IP protection policies and their latest changes, the special protection the Patent Law grants to pharmaceutical innovation, eight hot topics in innovator drug prosecution, strategies for responding to pharmaceutical patent invalidation, and pharmaceutical patent infringement practice.
On Site
Moments
Why Attend
Highlights
- 01
Innovator drug perspective with a full chain from institutions to prosecution, invalidation and litigation
- 02
Five instructors including a former patent examination department head, senior IP experts and practising litigators
- 03
Nearly 30 R&D and IP management professionals from pharmaceutical companies, with active on-site discussion
- 04
Jointly launched by the IP Practice Centre (BIPI) and Zhichan Huicui
Topics & Agenda
Key Topics
Institutions and policy
03- China's biopharma IP protection policies and their latest changes
- Special protection for pharmaceutical innovation under the Patent Law, covering supplementary data, Bolar exemption, compulsory licensing, term extension and patent linkage
- Regulatory rules and open questions on pharmaceutical test data protection
Prosecution and drafting
04- Eight hot topics in innovator drug patent prosecution
- Patent versus paper, portfolio planning and drafting for infringement purposes
- Patentability of chiral and formulation compounds
- Office action responses, supplementary experimental data and priority claims
Invalidation and litigation
03- Strategies for responding to pharmaceutical patent invalidation
- Patent linkage case practice, covering filing, trial and registration errors
- Combination therapy, centralised procurement enforcement and numerical feature equivalents
Overview of Speakers
Speakers
Qingkui Zhang
China National Intellectual Property Administration
Former Director, Chemistry Examination Dept. and Pharmaceuticals & Biotechnology Examination Dept.
Yongshun Cheng
Renowned IP Expert
Xiyuan Zheng
Beijing Qiancheng Law Firm
Deputy Director of Patent Centre, Partner
Xiaolei Li
Beijing Longnuo Law Firm
Partner
Yongquan Liu
Beijing Shining Law Firm
Partner
Hosted By
Organisers
MIPT-2024-BJ · see you at the next edition
For the full agenda or registration details, get in touch with the organising committee — we usually reply within one business day.
Full Report
Read the full post-event report
Originally published on our WeChat account, including the full session recap and photo gallery.